Publications by authors named "Sean Kraus"
Background And Objectives: Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative avelumab to standard treatments.
Methods: Patients with resectable E/GEJ cancers received avelumab with nCRT and adjuvant avelumab after resection.
Article Synopsis
- - Attempts to find specific cancer markers for colorectal cancer (CRC) have been unsuccessful, but cancer-associated fibroblasts (CAFs) show promise as they have unique markers that are not present in healthy tissues.
- - Among the CAF proteins studied, fibroblast activation protein (FAP) was found in 94.5% of CRC samples but was largely absent in normal tissues, suggesting it could be an effective target for antibody therapies.
- - The study also revealed that high levels of certain proteins (PDPN, MMP2, THY1) in CRC were linked to greater immune activity, indicating potential for developing new antibody-mediated treatments.
Purpose Of Review: To evaluate the clinical potential of chemokine receptor antagonists for the treatment of patients with cancer.
Recent Findings: Chemokine receptors and their ligands can have a significant impact on the infiltration of cells into the tumor microenvironment. The receptors are increasingly being investigated as targets for the treatment of cancers.
Stem and progenitor cell fate transitions constitute key decision points in organismal development that enable access to a developmental path or actively preclude others. Using the hematopoietic system, we analyzed the relative importance of cell fate-promoting mechanisms versus negating fate-suppressing mechanisms to engineer progenitor cells with multilineage differentiation potential. Deletion of the murine Gata2-77 enhancer, with a human equivalent that causes leukemia, downregulates the transcription factor GATA2 and blocks progenitor differentiation into erythrocytes, megakaryocytes, basophils, and granulocytes, but not macrophages.
View Article and Find Full Text PDFColorectal cancer (CRC) is the third most common malignancy worldwide. The presence of CD8 tumor-infiltrating T lymphocytes (TILs) is associated with improved prognosis and therapeutic response in CRC patients. FOLFOX chemotherapy is a standard first-line treatment for patients with CRC.
View Article and Find Full Text PDF